Syneron Medical Ltd (ELOS) Tops Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Syneron Medical Reports Third Quarter 2016 Revenue of $71.5 Million
November 9, 2016 7:01 AM ESTIRVINE, Calif., Nov. 9, 2016 /PRNewswire/ --Â Syneron Medical Ltd. (NASDAQ: ELOS), a leading global aesthetic device company, today announced financial results for the three month period ended September 30, 2016.
Third Quarter 2016 Financial Highlights:
Revenue of $71.5 million, up 15.3% year-over-year Product revenue up 18.6% year-over-year, including 19.5% North America and 18.1% international growth Emerging products revenue of $24.1 million, which represents the Company's strategic growth drivers, grew 61% year-over-year Total Body Shaping revenue of $14.2 million grew 46% year-over-year GAAP earnings per share of $0.02, compared to GAAP loss per... More